Back to results
US 2010/0143381 A1Published application
Lysophosphatidic acid receptor targeting for lung disease
OwnerAndrew Tager, Andrew D. Lusterinventors
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerAndrew Tager, Andrew D. Lusterinventors
Estimating the term…
The present invention contemplates that lysophosphatidic acid (LPA) may be induced by lung injury and may be responsible for aberrant wound-healing responses. For example, in a bleomycin model of pulmonary fibrosis LPAi deficient mice are protected from pulmonary fibrosis and mortality. Specifically, chemotactic-induced fibroblast responses, lung fibroblast accumulation, and vascular permeability increases were all attenuated. In contrast, however, bleomycin-induced leukocyte recruitment was preserved. These results demonstrate that LPAi activity may link pulmonary fibrosis with lung injury by mediating fibroblast recruitment and vascular leak. The present invention therefore represents LPAi as a new target to treat lung diseases including, but not limited to, fibrosis, idiopathic pulmonary fibrosis, and acute respiratory distress syndrome.
A method, comprising:
A method, comprising:
A method, comprising:
A method, comprising:
A kit comprising:
A kit comprising:
A kit comprising:
A kit comprising:
Dependencies are inferred from the claim text.